Expert review of pharmacoeconomics & outcomes research · 2025
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Berrichi Moustafa, Barka-Bedrane Zahira, Osmani Ahlam, Belahcen Karima, Hafsi Bouchra, Messaoudi Ines, Selka Mohammed Adil, Toumi Houari
Аннотация
BACKGROUND: Multiple sclerosis (MS) is a chronic neurodegenerative disease impacting young adults, reducing quality of life and imposing economic burdens.
OBJECTIVES: This study estimated MS costs in Algeria from a societal perspective, analyzed cost variations by disease severity, and provided insights for enhancing MS management and healthcare planning.
METHODS: A cross-sectional, bottom-up cost-of-illness study used a validated questionnaire to collect demographic, clinical, and socioeconomic data from MS patients. Data included disease-modifying therapy (DMT) use, MS course, and EDSS scores. Direct costs (medical and non-medical) and indirect costs (productivity losses from absenteeism and early retirement) were calculated. Cost drivers were analyzed using generalized linear models.
RESULTS: Among 354 patients, the total annual societal cost per MS patient was $9,636.5 (95% CI: 9101.2 -10,178), with a mean EDSS score of 3.1 (SD 2.1). Direct costs accounted for 93.31%, with DMTs comprising 94.42% of direct medical costs. Costs rose with disease severity, from $8,697.9 (95% CI: 8060.9-9326.8) for mild MS to $12,450.8 (95% CI: 10137.2 -14,773.6) for severe MS (p < 0.001).
CONCLUSIONS: This study highlights MS's economic burden in Algeria, with DMTs as the primary cost driver. Optimized resource allocation and cost-effective DMT strategies are essential to improve MS care.
OBJECTIVES: This study estimated MS costs in Algeria from a societal perspective, analyzed cost variations by disease severity, and provided insights for enhancing MS management and healthcare planning.
METHODS: A cross-sectional, bottom-up cost-of-illness study used a validated questionnaire to collect demographic, clinical, and socioeconomic data from MS patients. Data included disease-modifying therapy (DMT) use, MS course, and EDSS scores. Direct costs (medical and non-medical) and indirect costs (productivity losses from absenteeism and early retirement) were calculated. Cost drivers were analyzed using generalized linear models.
RESULTS: Among 354 patients, the total annual societal cost per MS patient was $9,636.5 (95% CI: 9101.2 -10,178), with a mean EDSS score of 3.1 (SD 2.1). Direct costs accounted for 93.31%, with DMTs comprising 94.42% of direct medical costs. Costs rose with disease severity, from $8,697.9 (95% CI: 8060.9-9326.8) for mild MS to $12,450.8 (95% CI: 10137.2 -14,773.6) for severe MS (p < 0.001).
CONCLUSIONS: This study highlights MS's economic burden in Algeria, with DMTs as the primary cost driver. Optimized resource allocation and cost-effective DMT strategies are essential to improve MS care.